JP2022506113A5 - - Google Patents

Info

Publication number
JP2022506113A5
JP2022506113A5 JP2021523282A JP2021523282A JP2022506113A5 JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5 JP 2021523282 A JP2021523282 A JP 2021523282A JP 2021523282 A JP2021523282 A JP 2021523282A JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5
Authority
JP
Japan
Prior art keywords
composition according
oxybutynin
hydroxyatomoxetine
receptor antagonist
muscarinic receptor
Prior art date
Application number
JP2021523282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506113A (ja
JPWO2020091862A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043065 external-priority patent/WO2020091862A1/en
Publication of JP2022506113A publication Critical patent/JP2022506113A/ja
Publication of JP2022506113A5 publication Critical patent/JP2022506113A5/ja
Publication of JPWO2020091862A5 publication Critical patent/JPWO2020091862A5/ja
Priority to JP2024062027A priority Critical patent/JP2024088740A/ja
Pending legal-status Critical Current

Links

JP2021523282A 2018-10-31 2019-07-23 睡眠時無呼吸を治療するための方法及び組成物 Pending JP2022506113A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024062027A JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
US62/753,420 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062027A Division JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2022506113A JP2022506113A (ja) 2022-01-17
JP2022506113A5 true JP2022506113A5 (https=) 2022-07-27
JPWO2020091862A5 JPWO2020091862A5 (https=) 2022-07-27

Family

ID=67539629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523282A Pending JP2022506113A (ja) 2018-10-31 2019-07-23 睡眠時無呼吸を治療するための方法及び組成物
JP2024062027A Pending JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024062027A Pending JP2024088740A (ja) 2018-10-31 2024-04-08 睡眠時無呼吸を治療するための方法及び組成物

Country Status (9)

Country Link
US (3) US20210401790A1 (https=)
EP (1) EP3873454A1 (https=)
JP (2) JP2022506113A (https=)
KR (1) KR20210084481A (https=)
CN (1) CN112930179A (https=)
AU (1) AU2019370091A1 (https=)
CA (1) CA3117766A1 (https=)
MX (2) MX2021004883A (https=)
WO (1) WO2020091862A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
MX2024007764A (es) * 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
US20250049779A1 (en) * 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
CN106714790A (zh) * 2014-07-22 2017-05-24 托马斯·P·杜利 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Similar Documents

Publication Publication Date Title
CN101730530B (zh) 他喷他多的滴定
JP2022506113A5 (https=)
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
US20260014163A1 (en) Use of reboxetine to treat fibromyalgia
JP6479670B2 (ja) ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2006503918A5 (https=)
JP2020517719A5 (https=)
JP2006503918A (ja) ミルナシプランの改変放出組成物
JPH08208471A (ja) 薬物反応の増強作用
JP2008524332A5 (ja) 睡眠障害のための医薬組成物
JP2025084754A5 (https=)
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US11364245B2 (en) Use of reboxetine to treat narcolepsy
US20210100808A1 (en) Use of reboxetine to treat narcolepsy
CN103041389A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
JP2006506461A (ja) ミルナシプランのパルス型放出組成物
US20070219201A1 (en) Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
JPWO2020091862A5 (https=)
JPWO2020163785A5 (https=)
US20240415842A1 (en) Use of reboxetine to treat narcolepsy
TW202128179A (zh) 瑞波西汀治療神經系統障礙的用途
CN116194092A (zh) 经口给予制剂
IL293536A (en) Use of reboxetine to treat disease states in the nervous system
JPWO2023118123A5 (https=)
HK1233916A1 (en) Titration of tapentadol